Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ingenol Mebutate in Actinic Keratosis
NCT02124239Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Apr 2014
- Primary completion
- Nov 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ingenol mebutate in actinic keratosis (AK) (3 arms), sponsored by LEO Pharma. Primary endpoints: Area under the plasma concentration versus time curve and Peak Plasma Concentration. Started Apr 2014; status: completed.
02
Drugs
ingenol mebutate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02124239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124239.